Novel Health Strategies (United States)
- Research works
- 85 ▲ 546% vs 2013–17
- Citations
- 816 9.6 per fractional work
- Top-10% rate
- 1.5% record average 16.5%
- Open access
- 40% world 28%
Not ranked overall: Novel Health Strategies (United States) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Economics, Econometrics and Finance, 8.7×. Every wedge is a field page.
- Economics, Econometrics and Finance 8.7×
- Dentistry 4.9×
- Immunology and Microbiology 3.5×
- Medicine 2.7×
- Biochemistry, Genetics and Molecular Biology 1.9×
- Health Professions 1.4×
- Materials Science 0.9×
- Neuroscience 0.8×
- Nursing 0.7×
- Business, Management and Accounting 0.5×
- Engineering 0.1×
- Agricultural and Biological Sciences 0.1×
- Environmental Science 0.0×
Who are the top researchers at Novel Health Strategies (United States)?
Ranked on the composite score, S. Aggarwal, O. Topaloglu and Sachin Kumar lead among researchers whose main affiliation is Novel Health Strategies (United States).
- 1 S. Aggarwal United States · #1,290,040 worldwide 21 citations · 56 works
- 2 O. Topaloglu United States · #1,520,441 worldwide 0 citations · 26 works
- 3 Sachin Kumar United States · #1,605,940 worldwide 7 citations · 17 works
Which keywords describe research at Novel Health Strategies (United States)?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Quality of Life, Cost-effectiveness Analysis, Health Utility Measures, Epidemiology, Treatment, Clinical Practice Guidelines, Genetics and Inflammatory Bowel Disease.
- Oropharyngeal Cancer
- Primary Immunodeficiency
- Microscopic Colitis
- TDP-43
- FUS/TLS
- Prognostic Factors
- Prevention
- Ulcerative Colitis
- Immunology
- Chronic Venous Insufficiency
- Regulatory Challenges
- Radiotherapy
- Crohn's Disease
- Risk Factors
- Artificial Intelligence
- Inflammatory Bowel Disease
- Big Data
- Clinical Practice Guidelines
- Health Utility Measures
- Epidemiology
- Quality of Life
- Cost-effectiveness Analysis
- Treatment
- Genetics
- Diagnosis
- Pathogenesis
- Chemotherapy
- Clinical Trials
- Patient Safety
- Cardiovascular Disease
- Stem Cell Regulation
- Genetic Variants
- Squamous Cell Carcinoma
- Varicose Veins
- Primary Care
- Prophylaxis
- Guidelines
- Collagenous Colitis
- Photodynamic Therapy
- Human Papillomavirus
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Quality of Life10▲ 14×8 topics
- Epidemiology9▲ 4.2×17 topics
- Cost-effectiveness Analysis8▲ 164×1 topic
- Health Utility Measures8▲ 164×1 topic
- Treatment4▲ 6.3×8 topics
- Clinical Practice Guidelines4▲ 12×5 topics
- Genetics3▲ 8.3×3 topics
- Big Data3▲ 6.2×2 topics
- Diagnosis3▲ 6.0×4 topics
- Inflammatory Bowel Disease3▲ 46×2 topics
- Pathogenesis3▲ 10×2 topics
- Artificial Intelligence2▲ 3.4×1 topic
- Chemotherapy2▲ 6.4×4 topics
- Risk Factors2▲ 4.1×3 topics
- Clinical Trials2▲ 6.5×3 topics
- Crohn's Disease2▲ 48×2 topics
- Patient Safety2▲ 25×2 topics
- Radiotherapy2▲ 9.6×3 topics
- Cardiovascular Disease2▲ 3.2×5 topics
- Regulatory Challenges2▲ 38×1 topic
- Stem Cell Regulation2▲ 150×1 topic
- Chronic Venous Insufficiency2▲ 154×1 topic
- Genetic Variants2▲ 18×2 topics
- Immunology2▲ 29×1 topic
- Squamous Cell Carcinoma2▲ 36×2 topics
- Ulcerative Colitis2▲ 70×1 topic
- Varicose Veins2▲ 154×1 topic
- Prevention2▲ 6.7×3 topics
- Primary Care2▲ 7.4×3 topics
- Prognostic Factors1▲ 6.2×4 topics
- Prophylaxis1▲ 21×2 topics
- FUS/TLS1▲ 108×1 topic
- Guidelines1▲ 5.3×2 topics
- TDP-431▲ 108×1 topic
- Collagenous Colitis1▲ 91×1 topic
- Microscopic Colitis1▲ 91×1 topic
- Photodynamic Therapy1▲ 9.8×3 topics
- Primary Immunodeficiency1▲ 73×1 topic
- Human Papillomavirus1▲ 17×1 topic
- Oropharyngeal Cancer1▲ 42×1 topic
Which research topics does Novel Health Strategies (United States) publish most on?
By volume in 2022–2025: Health Systems, Economic Evaluations, Quality of Life, Artificial Intelligence in Healthcare and Education, Biomedical Ethics and Regulation and Diagnosis and Treatment of Venous Diseases.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Health Systems, Economic Evaluations, Quality of Life Economics and Econometrics 8 works
- 2 Artificial Intelligence in Healthcare and Education Health Informatics 2 works
- 3 Biomedical Ethics and Regulation Physiology 2 works
- 4 Diagnosis and Treatment of Venous Diseases Surgery 2 works
- 5 Inflammatory Bowel Disease Genetics 2 works
- 6 Amyotrophic Lateral Sclerosis Research Neurology 1 works
- 7 Immunodeficiency and Autoimmune Disorders Immunology 1 works
- 8 Microscopic Colitis Epidemiology 1 works
- 9 Head and Neck Cancer Studies Otorhinolaryngology 1 works
- 10 Oral Health Pathology and Treatment Periodontics 1 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Novel Health Strategies (United States)'s research output changed?
Output in 2018–2022 was 546% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Chevy Chase
- Howard Hughes Medical Institute
- American Society of Addiction Medicine
- Stanley Medical Research Institute
- National Retina Institute
- Posnick Center for Facial Plastic Surgery
- The School of Theoretical Modeling
- UsAgainstAlzheimer
- National 4-H Council
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.